$LUPIN

Lupin are likely to remain in focus after the drugmaker announced that it has received tentative approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Enzalutamide Tablets in strengths of 40 mg, 80 mg, 120 mg, and 160 mg. The USFDA has tentatively approved the 40 mg and 80 mg strengths as bioequivalent to Astellas' Xtandi tablets. While Xtandi is currently marketed in 40 mg and 80 mg strengths, Lupin's tentatively approved 120 mg and 160 mg formulations are expected to offer healthcare providers and patients greater dosing flexibility. Earlier this month, Lupin launched Azilsartan Medoxomil Tablets in 40 mg and 80 mg strengths in the U.S. following USFDA approval. The company also recently secured USFDA approval for Ranluspec™ (ranibizumab-hkdz). In addition, Lupin, in partnership with Natco Pharma, received USFDA approval for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials.